LambdaTest

NuScale Power is a pioneering company in small modular reactor (SMR) technology, offering innovative and scalable nuclear power solutions. Their flagship product, the NuScale Power Module (NPM), represents a significant advancement in nuclear energy. ### NuScale Power Module (NPM) - The NPM is a 250 megawatts thermal (MWt) integral pressurized water reactor (PWR). - Each module measures 76 feet tall and 15 feet in diameter, generating 77 megawatts electric (MWe) of electricity. - It utilizes gravity-driven natural circulation for primary coolant in both normal operation and shutdown modes. ### Design and Safety Features - The NPM integrates the reactor core, steam generators, pressurizer, and containment within a single pressure vessel. - Modules are submerged in a below-grade pool of water within a Seismic Category 1, aircraft impact-resistant building. - Passive safety systems can cool and depressurize the containment vessel even during a loss of external power. ### Scalability and Flexibility - NuScale's VOYGR power plant design can accommodate up to 12 NPMs, with a total gross output of 924 MWe. - Smaller configurations include VOYGR-4 (308 MWe) and VOYGR-6 (462 MWe) plants. - The design allows for incremental plant capacity growth with minimal operational disruption. ### Operational and Maintenance Aspects - Fuel: Less than 4.95% enriched UO2 with a 24-month fuel cycle. - Underwater refueling allows continuous operation of other plant modules. - 60-year design life with a high capacity factor of 92-95%. ### Global Interest and Partnerships - NuScale is collaborating with over a dozen governments and organizations worldwide. - Significant interest in VOYGR plants across the United Kingdom, Europe, the Middle East, Africa, and Asia. ### Regulatory and Technological Maturity - The design leverages 50 years of light-water-cooled PWR technology. - Many systems and components are at a high technology readiness level (TRL). NuScale Power's SMR technology aims to provide a smarter, cleaner, safer, and cost-competitive solution for diverse electrical and process heat applications, positioning the company at the forefront of next-generation nuclear energy.

Citigroup Inc., commonly known as Citi, is a multinational investment bank and financial services company headquartered in New York City. With a rich history dating back to 1812, Citi has evolved into one of the world's leading financial institutions. ## History and Formation Founded as the City Bank of New York in 1812, Citi has grown through numerous mergers and innovations. A significant milestone was the 1998 merger of Citicorp and Travelers Group, forming Citigroup. However, Travelers was spun off in 2002. ## Structure and Operations Citi operates through two major divisions: 1. Institutional Clients Group (ICG): Offers investment banking, corporate banking, treasury and trade solutions, and securities services. 2. Personal Banking and Wealth Management (PBWM): Includes retail banking, credit card services, and wealth management. The company provides a wide range of financial services, including: - Retail, commercial, and investment banking - Securities brokerage - Trade and securities services - Wealth management solutions - Accounts and deposit services - Loans and mortgages - Small business banking solutions - Corporate and institutional services ## Global Presence Citi maintains a significant global footprint, serving clients in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific region. Its diverse client base includes individuals, corporations, small businesses, and institutional and government entities. ## Key Initiatives and Innovations - Pioneered the world's first ATM and introduced 24-hour PC banking in the UK - Implemented Smart Banking branches and 24-hour service units globally - Launched innovative credit card products and expanded retail banking operations - Committed to diversity and inclusion (D&I) and environmental, social, and governance (ESG) initiatives ## Leadership Jane Fraser became CEO in February 2021, making history as the first woman to lead a major Wall Street firm. Under her leadership, Citi has intensified its focus on addressing social issues, including the U.S. racial wealth gap through its Action for Racial Equity initiative. ## Financial Status As one of the Big Four banking institutions in the United States, Citi is considered a systemically important bank by the Financial Stability Board. It consistently ranks among the top global investment banks and maintains a strong position in various financial rankings: - #24 in the Forbes Global 2000 (2023) - 36th on the Fortune 500 (2023) Citi's continued evolution and adaptation to the changing financial landscape solidify its position as a key player in the global banking industry.

Aviceda Therapeutics is a private, clinical-stage biotechnology company based in Cambridge, Massachusetts. The company specializes in developing next-generation immunomodulators to address various diseases, with a particular focus on those involving the innate immune system and chronic, non-resolving inflammation. ### Key Focus Areas - **Glyco-Immune Therapeutics**: Aviceda s proprietary Glyco-Code technology platform and High Affinity Ligands of Siglecs (HALOS™) nanotechnology are leveraged to modulate the innate immune response. This innovative approach targets glyco-immune checkpoints and exploits interactions between glycans and innate immune cells. ### Therapeutic Pipeline 1. **Ophthalmology**: - AVD-104: An intravitreal glycomimetic nanoparticle for geographic atrophy (GA) secondary to age-related macular degeneration. Currently in Phase 2b/3 clinical trials. - AVD-302: In development for diabetic retinopathy. - AVD-401: Targeting retinoblastoma. 2. **Other Indications**: - AVD-601: Oncology - AVD-701: Neurology - AVD-801 and AVD-901: Fibrosis ### Technology and Platforms 1. **Cell-Based High-Throughput Screening (HTS)**: Enables rapid screening, selection, and optimization of ligands with high affinity and specificity for innate immune cells. 2. **Nanoparticle Technology**: Proprietary delivery system for therapeutics, exemplified by the glycan-coated nanoparticles in AVD-104. ### Funding and Development Aviceda recently secured $207.5 million in Series C financing to advance its lead program, AVD-104, into pivotal trials. This substantial funding was backed by prominent healthcare funds and investors, demonstrating strong confidence in the company s potential. ### Leadership and Expertise The company boasts a cross-disciplinary team of recognized scientists, clinicians, and drug developers. Following the Series C financing round, Aviceda expanded its board of directors with industry experts, further strengthening its leadership position. In conclusion, Aviceda Therapeutics is well-positioned to address a wide range of inflammatory, degenerative, and fibrotic diseases through its innovative glyco-immune therapeutics and advanced technology platforms. The company s robust pipeline, cutting-edge technology, and strong financial backing make it a notable player in the biotechnology industry.